MC38 neoantigen (AdpgkMUT)-specific CD8+ T cells markedly accumulated in tumor sites following treatment with the Bpmel-OVA cell adjuvant compared with OVA protein immunization, whereas OVA-specific immune responses were observed in both treatments (Fig. 1 G and Fig. S1 K). This evidence concerns the gene CD8A and neoplasm.